Celebrex and Bextra Manufacturer to Settle Lawsuits

According to the Wall St. Journal, Pfizer is starting to settle lawsuits against its painkilling drugs Celebrex and Bextra. While the numbers are not yet official, one attorney told the Journal that he was offered $200,000 per client for his Bextra clients while he was offered $40-50,000 per client for his Celebrex cases.
Pfizer appears to be handling their cases differently than Merck whose product Vioxx is in the same class of painkilling drugs. All are classified as Cox-2 inhibitors which have come under intense scrutiny because they’ve been linked to an increased risk of heart attack and stroke.